We previously demonstrated that low biosynthesis of v-3 fatty acid-derived proresolution mediators, termed protectins, is associated with an impaired global resolution capacity, inflammation and insulin resistance in obese high-fat diet-fed mice 1 . These findings prompted a more direct study of the therapeutic potential of protectins for the treatment of metabolic disorders. Herein we show that protectin DX (PDX) exerts an unanticipated glucoregulatory activity that is distinct from its anti-inflammatory actions. We found that PDX selectively stimulated the release of the prototypic myokine interleukin-6 (IL-6) from skeletal muscle and thereby initiated a myokine-liver signaling axis, which blunted hepatic glucose production via signal transducer and activator of transcription 3 (STAT3)-mediated transcriptional suppression of the gluconeogenic program. These effects of PDX were abrogated in Il6-null mice. PDX also activated AMP-activated protein kinase (AMPK); however, it did so in an IL-6-independent manner. Notably, we demonstrated that administration of PDX to obese diabetic db/db mice raises skeletal muscle IL-6 levels and substantially improves their insulin sensitivity without any impact on adipose tissue inflammation. Our findings thus support the development of PDX-based selective muscle IL-6 secretagogues as a new class of therapy for the treatment of insulin resistance and type 2 diabetes. PDX ((10S,17S)-dihydroxydocosa-(4Z,7Z,11E,13Z,15E,19Z)-hexaenoic acid), is produced via sequential lipoxygenation of docosahexaenoic acid (DHA; 22:6 n-3) 2,3 and can be found together with the first identified protectin, protectin D1 (PD1; (10R,17S)-dihydroxydocosa-(4Z,7Z,11E,13E,15Z,19Z)-hexaenoic acid), in mouse inflammatory exudates 2 . PDX may also be produced by human neutrophils exposed to DHA, albeit to a lesser extent than PD1 (ref. 2) . We evaluated the therapeutic potential of PDX for insulin resistance in the setting of lipid excess by employing a 6-h heparinized intralipid infusion paired to a hyperinsulinemic-euglycemic clamp in lean C57BL/6 mice ( Supplementary Fig. 1 ). We administered equal volumes of ethanol vehicle or PDX (1 µg intravenously (i.v.)) to lipidinfused mice immediately before and 2.5 h into the 6-h lipid infusion. We also clamped a saline-infused group that had been treated with vehicle to ascertain baseline insulin sensitivity. Preclamp glycemia was lower in PDX-treated mice compared to both saline-infused and lipidinfused animals treated with vehicle ( Fig. 1a) ; however, preclamp insulinemia was not different among groups at this time point (saline, 1.4 ± 0.17 ng ml −1 ; lipid, 1.7 ± 0.09 ng ml −1 ; lipid + PDX, 1.5 ± 0.02 ng ml −1 ; data are mean ± s.e.m., n = 6). Thus, PDX appeared to possess an unanticipated insulin-independent glucoregulatory activity.
PDX-treated mice were also protected from lipid-induced insulin resistance, as demonstrated by a higher glucose infusion rate (GIR) required to maintain euglycemia during the clamp in these mice compared to vehicle-treated, lipid-infused mice (Fig. 1a,b) . The better insulin response in PDX-treated, lipid-infused animals involved partial protection of peripheral insulin action and markedly elevated hepatic insulin action (Fig. 1c) . Phosphorylation of protein kinase B (Akt) on Ser473 confirmed the stronger insulin response in skeletal muscle and liver of PDX-treated mice compared to vehicle-treated, lipid-infused counterparts ( Fig. 1d,e ).
In line with the classical role of protectins in the active resolution of inflammation, we found that PDX also prevented lipid-mediated induction of inducible nitric oxide synthase (iNOS) in both muscle and liver ( Fig. 1d,e ) and c-Jun N-terminal kinase (JNK) activation in liver, as determined by phosphorylation on Thr183 and Tyr185 (Thr183/Tyr185) ( Fig. 1e) . PDX also strongly suppressed lipidinduced secretion of chemokine cc motif ligand 2 (CCL2) and CCL5, as well as tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ), interleukin-1β (IL-1β), IL-2 and IL-17 ( Fig. 1f) . However, in contrast to all other chemokines and cytokines tested, IL-6 concentrations were approximately sevenfold higher in PDX-treated mice compared to in mice that received lipid infusion alone ( Fig. 1f) . Although IL-6 has been reported to underlie the insulin-sensitizing actions of adiponectin in liver 4 , we found that adiponectin does not account for these higher concentrations of IL-6 in PDX-treated mice, as both vehicle-and PDX-treated lipid-infused mice displayed similarly low concentrations of adiponectin in plasma compared to saline-infused animals ( Supplementary Fig. 2a ).
As macrophages are important contributors to global chemokine and cytokine production, we next examined whether PDX had the same influence on the lipid-induced inflammatory response exhibited by macrophages treated with palmitate in vitro. PDX effectively suppressed lipid-induced secretion of CCL2, CCL5, TNF-α, IL-2 and IL-10, as well as iNOS and JNK activation ( Supplementary  Fig. 2b-d) . However, rather than stimulating IL-6 release, PDX repressed lipid-induced IL-6 production in macrophages ( Supplementary Fig. 2b) . These data suggest that the higher concentration of circulating IL-6 in PDX-treated mice was probably derived from an alternate cellular source.
Given that IL-6 is well regarded as the prototypic 'myokine' (muscle-derived cytokine) 5,6 , we hypothesized that skeletal muscle could be the site of higher IL-6 release in PDX-treated animals. Notably, we found that the effect of PDX on IL-6 in muscle closely resembled that in plasma ( Fig. 2a) , but the livers of PDX-treated mice did not contain higher IL-6 concentrations than those from vehicletreated mice (Supplementary Fig. 3a) .
To confirm that PDX induces IL-6 expression and release from muscle in a cell-autonomous fashion, we next treated cultured C2C12 myotubes with PDX. PDX stimulated a dose-dependent rise in IL-6 mRNA expression and protein accumulation in medium within 2 h of administration, with the greatest dose prompting more than twofold higher IL-6 secretion and mRNA expression than vehicle ( Fig. 2b) . We also detected greater phosphorylation of AMPK at this time point in PDX-treated myotubes ( Fig. 2c) .
Brown adipose tissue has recently been shown to regulate glucose homeostasis via secretion of IL-6 (ref. 7). However, although we observed IL-6 release from cultured T37i brown adipocytes in response to adrenergic stimuli (1 µM norepinephrine), PDX did not stimulate IL-6 release from this cell type ( Supplementary Fig. 3b ). We also found that PDX neither stimulated nor repressed IL-6 release or mRNA expression in macrophages that had not been treated with palmitate ( Supplementary Fig. 3c,d) . Despite its lack of effect on IL-6 release, PDX maintained its ability to promote AMPK phosphorylation ( Supplementary Fig. 3e ). Activation of AMPK represses inflammatory cytokine production in activated macrophages 8 and thus may underlie the PDX-mediated inhibition of IL-6 release in our earlier macrophage studies with palmitate.
To determine the structural specificity of PDX-mediated muscle IL-6 release, we next assessed the potential of three structurally related lipid mediators, PD1, (8S,15S)-dihydroxyicosa-(5Z,9E,11Z,13E)tetraenoic acid ((8S,15S)-diHETE) and (7S,8R,17S)-trihydroxydocosa-(4Z,9E,11E,13Z,15E,19Z)-hexaenoic acid (resolvin D1), to stimulate IL-6 production from C2C12 myotubes. We chose these lipids because they possess a broad range of common structural features with PDX ( Supplementary Fig. 3f ). However, only administration of PDX prompted IL-6 release from muscle cells ( Supplementary Fig. 3f ). These comparative structure-function analyses thus revealed that the ability of PDX to trigger IL-6 release was not solely dependent on the DHA backbone, or on the number, position and stereochemistry of the hydroxyl groups alone, and cannot simply be linked to the E,Z,E organization of the conjugated triene within the PDX molecule. Thus, skeletal muscle IL-6 release appears to be a unique consequence of stimulation by the PDX molecule rather than a shared feature of a new lipid class. Together, these data identify PDX as a structurally distinct selective skeletal muscle IL-6 secretagogue.
IL-6 is thought to regulate hepatic glucose production in liver via STAT3-mediated transcriptional suppression of the gluconeogenic genes peroxisome proliferator-activated receptor γ coactivator-1α (Ppargc1a), phosphoenolpyruvate carboxykinase (Pck1) and glucose-6-phosphatase (G6pc) 9, 10 . We observed that PDX promotes greater STAT3 phosphorylation in liver compared to vehicle-treated saline-or lipid-infused mice (Fig. 2d) . The suppression of Ppargc1a and Pck1 in liver of PDX-treated mice was also greater than that observed in vehicletreated mice ( Fig. 2e) , and there was also improved suppression of npg G6pc in PDX-treated animals compared to vehicle-treated, salineinfused mice ( Fig. 2e) . In line with a reported role for AMPK in IL-6mediated enhancement of skeletal muscle glucose metabolism [11] [12] [13] , PDX-treated mice also displayed more phosphorylation of AMPK in muscle compared to their vehicle-treated counterparts ( Fig. 2f) .
To confirm the involvement of IL-6 in the beneficial effects of PDX, we next performed a second round of paired lipid-infusion hyperinsulinemic-euglycemic clamp studies in Il6-knockout mice alongside genetically matched wild-type (WT) nonlittermate counterparts. We added saline-infused mice treated with PDX to the study to ascertain whether PDX also improves glucose metabolism in insulin-sensitive animals ( Supplementary Fig. 4 ).
As observed in the previous study, lipid-infused PDX-treated WT mice displayed lower preclamp glycemia compared to vehicle-treated counterparts ( Fig. 3a) in the absence of any change in circulating insulin (data not shown). However, this effect of PDX was completely absent in Il6-knockout mice (Fig. 3a) . Lipid-infused Il6-knockout mice were also refractory to the PDX-mediated enhancement of GIR (Fig. 3b) , and although PDX improved both peripheral and hepatic insulin action in lipid-infused WT mice ( Fig. 3c) , these effects were substantially blunted in Il6-knockout mice.
As expected, PDX also failed to raise IL-6 concentrations in skeletal muscle of lipid-infused Il6-knockout mice ( Fig. 3d) . Accordingly, the stimulatory effect of PDX on hepatic STAT3 phosphorylation ( Fig. 3e ) and its suppressive effect on hepatic Ppargc1a, Pck1 and G6pc (Fig. 3f) were completely absent in lipid-infused Il6-knockout mice. Il6-knockout mice also had higher Pck1 expression compared to vehicle-treated WT mice ( Fig. 3f) ; however, this was not the case for G6pc, whose expression was significantly lower in Il6-knockout mice compared to in vehicle-treated WT counterparts (Fig. 3f) . This discrepant effect of IL-6 deficiency on Pck1 and G6pc expression may explain the lack of further deterioration of hepatic insulin action in lipid-infused Il6-knockout mice.
We observed similar effects of PDX on preclamp glycemia, GIR and skeletal muscle IL-6 concentration in insulin-sensitive salineinfused WT mice ( Supplementary Fig. 4a,b,d) . However, in contrast to the case in lipid-infused mice, the improved insulin sensitivity witnessed in the WT PDX-treated, saline-infused mice was entirely the result of superior hepatic insulin action (Supplementary Fig. 4c ). Of note, the IL-6-dependent activation of STAT3 by PDX was not associated with further suppression of Ppargc1a in insulin-sensitive saline-infused mice ( Supplementary Fig. 4e,f) . However, PDX administration did potentiate the transcriptional repression of Pck1 downstream of Ppargc1a (Supplementary Fig. 4f ). These effects of PDX on STAT3 and Pck1 were completely absent in saline-infused Il6knockout mice. PDX administration improved, though not in a statistically significant manner, the suppression of G6pc in saline-infused WT mice (P = 0.0614; Supplementary Fig. 4f ), but this was not the case for Il6-knockout counterparts. The expression of Pck1 and G6pc in PDX-treated, saline-infused Il6-knockout mice was higher than in vehicle-treated WT mice ( Supplementary Fig. 4f ), which is consistent with the reduced hepatic insulin action in these mice ( Supplementary  Fig. 4c ). It is noteworthy that PDX improved the inhibition of hepatic glucose output and suppression of gluconeogenic enzymes in these insulin-sensitive saline-infused mice without potentiating Akt phosphorylation ( Supplementary Fig. 5a ), which suggests that the hepatic STAT3 axis is the major pathway responsible for the glucoregulatory effects of PDX.
We also found that PDX-treated Il6-knockout mice exhibit comparable AMPK phosphorylation to PDX-treated WT mice ( Fig. 3g and Supplementary Fig. 4g ). In light of these data, we reexamined the early timeline of PDX-mediated IL-6 release and AMPK activation in C2C12 myotubes. PDX promoted AMPK phosphorylation within 30 min in these cells, but we did not detect IL-6 release into the medium at this time point (Supplementary Fig. 5b,c) . We also found that PDX maintained its ability to potently suppress lipid-induced elevations in npg circulating TNF-α in Il6-knockout mice (Supplementary Fig. 5d ). Thus, our data suggest that the major glucoregulatory mechanisms of PDX are distinct from its anti-inflammatory actions and its ability to activate AMPK.
We further explored the therapeutic efficacy of PDX in genetically obese db/db mice, a well-established model of type 2 diabetes. In these experiments, we treated db/db mice with vehicle or PDX (2 µg i.v.) 240 and 90 min before the initiation of a hyperinsulinemic-isoglycemic clamp. As observed previously, PDX tended to lower preclamp glycemia ( Fig. 4a) , but this effect did not reach statistical significance in these severely diabetic mice. Nonetheless, PDX treatment substantially improved insulin sensitivity, as revealed by a 3.6-fold higher GIR in PDX-treated mice compared to vehicle-treated animals (Fig. 4b) .
It is noteworthy that in these obese diabetic mice, the impact of PDX on GIR began to dissipate around 80 min into the clamp. This aligns well with a lack of enhanced STAT3 signal in liver at the completion of the clamp (Supplementary Fig. 5e ) and a recent report showing that obese mice express threefold higher levels of 15-hydroxyprostaglandin dehydrogenase, which is responsible for the enzymatic conversion of docosanoid resolution mediators to less active oxo-derivatives 14 . Nevertheless, we still observed greater suppression of Ppargc1a, Pck1 and G6pc in liver of PDX-treated db/db mice compared to vehicletreated counterparts (Fig. 4c) . Of note, these effects occurred in the absence of any significant anti-inflammatory impact of PDX on adipose tissue chemokines or cytokines (Fig. 4d) . However, as observed in earlier studies, PDX-treated mice exhibited higher IL-6 concentrations in skeletal muscle and plasma (Fig. 4e) .
In order to determine whether the beneficial effects of PDX could be sustained or improved with a prolonged treatment regimen, we next administered 2 µg of PDX or vehicle to 17-week-old db/db mice twice daily for 5 d leading up to the clamp experiment. As in the acute study, PDX administration tended to lower glycemia without affecting circulating insulin ( Supplementary Fig. 6a,b) ; however, this change in glycemia did not reach significance in these severely obese diabetic mice. Nonetheless, the improved insulin sensitivity observed in db/db mice treated acutely with PDX was conserved in those mice treated with PDX for 5 d (Supplementary Fig. 6c ) and was once again associated with higher concentrations of skeletal muscle IL-6 and a trend toward higher plasma IL-6 levels ( Supplementary  Fig. 6d) . Thus, the effectiveness of PDX does not appear to dissipate with extended treatment. As the lengthening of the PDX treatment regimen to 5 d was not sufficient to resolve inflammatory cytokine production in adipose tissue or plasma of these very obese diabetic mice (Supplementary Fig. 6e,f) , it appears that the glucoregulatory axis of PDX action is entirely responsible for the improved glucose utilization observed in these obese diabetic mice.
To the best of our knowledge, this is the first report of an agent other than contraction or exercise that selectively promotes skeletal muscle IL-6 expression and release. The notable insulin-sensitizing effect of PDX observed in our animal models of insulin resistance and type 2 diabetes suggests that skeletal muscle IL-6 secretagogues could become a new class of agents for diabetes therapy. Further study of the mechanisms by which PDX promotes muscle IL-6 release is thus warranted. This is also, to our knowledge, the first report where Il6-knockout mice have been studied using the hyperinsulinemic-euglycemic clamp in conditions of lipid excess. Although lipid infusion and palmitate treatment do increase systemic and macrophage IL-6 production, immunoblots for pSTAT3 Ser727 and total STAT3 (e) and relative mRNA expression of Ppargc1a, Pck1 and G6pc normalized to Gapdh (f) in liver from clamped WT or Il6-knockout lipid-infused mice treated with PDX or vehicle. Dashed lines indicate that lanes were run on the same gel but were noncontiguous. Quantification of densitometry analyses for immunoblots is shown below the representative gels. (g) Immunoblots for pAMPK Thr172 and total AMPK in gastrocnemius muscle from clamped WT or Il6-knockout lipid-infused mice treated with PDX or vehicle. Dashed lines indicate that lanes were run on the same gel but were noncontiguous. Quantification of densitometry analyses for immunoblots is shown below the representative gels. WT-LV, n = 6 mice; WT-LP, n = 5 mice; KO-LV, n = 5 mice; KO-LP, n = 6 mice. Data are mean ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001 calculated using ANOVA. npg studies in Il6-knockout mice revealed that PDX-dependent AMPK activation and TNF-α repression in the absence of IL-6 is not sufficient to entirely prevent the onset of lipid-induced insulin resistance. Although we cannot rule out the possibility that higher AMPK activation is required in concert with release of IL-6 to elicit the glucoregulatory effects of PDX, we did find that PDX treatment improves insulin sensitivity in obese db/db mice without affecting the inflammatory phenotype of these animals. Further studies are therefore warranted in animals lacking AMPK to determine what role AMPK might have in the glucoregulatory and anti-inflammatory activities of PDX. It may also be possible that AMPK activation is necessary for PDX-mediated IL-6 release.
In conclusion, our studies identify the docosanoid resolution mediator, PDX, as an agent that carries a previously uncharacterized potent therapeutic potential for lipid-induced and obesity-linked insulin resistance and type 2 diabetes. PDX enhances both hepatic and peripheral glucose metabolism in vivo by promoting release of the prototypic myokine, IL-6. Notably, PDX stimulates skeletal muscle IL-6 release in a cell-specific manner that is very selective to the chemical structure of PDX. These findings may lead to the development of PDX-based muscle IL-6 secretagogues as a new class of drugs for the treatment of insulin resistance and type 2 diabetes.
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We thank C. Dion for surgical preparation of the mice and S. Pelletier for assistance with the palmitate macrophage studies. We also thank C. Serhan respectively, our findings do not support a role for IL-6 in the development of lipid-induced insulin resistance 15, 16 , as we found that lack of IL-6 does not prevent insulin resistance in lipid-infused mice. To the contrary, we found that insulin-sensitive saline-infused Il6-knockout mice display a slight defect in hepatic insulin action that is associated with altered regulation of hepatic Pck1 and G6pc. Our data thus join a growing body of work 4, 11, [17] [18] [19] that argues for a positive role of IL-6 in the regulation of glucose metabolism. We found that in addition to potentiating insulin action, PDX administration also induced a characteristic lowering of basal glycemia that was IL-6 dependent and preceded insulin administration in both saline-and lipid-infused mice. In additional studies performed in nonclamped mice, we observed that this PDX-dependent glucoselowering effect lasts for approximately 2.5 h in lean mice (data not shown). This suggests that PDX and IL-6 might also represent promising therapeutic targets as insulin-independent glucose-lowering agents. This finding is in agreement with work demonstrating that exposure of mouse soleus to IL-6 and soluble IL-6 receptor increases glucose transport ex vivo 20 and with a study showing that the hypoglycemic response to endotoxemia is absent in Il6-knockout mice 21 . Notably, our data suggest that the glucose-lowering effect of PDX is dependent on IL-6-mediated activation of hepatic STAT3, which suppresses the expression of Ppargc1a, Pck1 and G6pc 10 .
In addition to showing the insulin-sensitizing and glucoregulatory actions of PDX, this is also, to our knowledge, the first report demonstrating that PDX can suppress lipid-induced inflammation. In light of a recent report 19 that IL-6 promotes alternate activation of macrophages in inflammatory conditions such as obesity and endotoxemia by stimulating higher expression of the IL-4 receptor, it seems possible that IL-6 could underlie most of the anti-inflammatory activity of PDX. However, herein we observed PDX-dependent anti-inflammatory activity in two experimental paradigms in which IL-6 secretion was either repressed by PDX treatment (Supplementary Fig. 2) or not present due to genetic deletion of Il6 (Supplementary Fig. 4d ). Thus, our data suggest that the intrinsic anti-inflammatory activity of PDX does not hinge upon skeletal muscle IL-6 release. Alternatively, it is plausible that IL-6-independent activation of AMPK might underlie part of the anti-inflammatory activity of PDX 22, 23 . Nonetheless, our 
ONLINe MeTHODS
Animal studies. 14-week-old male C57BL/6 mice from Jackson Labs were used for the first paired lipid infusion hyperinsulinemic-euglycemic clamp study. These mice were placed on a standard laboratory chow diet with free access to food and water and kept in a 12-h light-dark cycle at the Laval University Hospital Research Center Animal Facility. Mice were randomly assigned to saline, lipid or lipid + PDX groups. Five days before the experiment, mice were anesthetized, and PE-10 catheters (Harvard Apparatus, QC, Canada) were inserted into the left common carotid artery and the right jugular vein for blood sampling and infusions, respectively. Mice were fasted for 5 h leading up to the protocol. Immediately before the start of the lipid infusion, PDX (1 µg) or an equal volume of vehicle was administered via the jugular catheter to each group. Mice were then infused for 6 h with saline (5 ml per kg body weight per hour) or lipid (20% intralipid emulsion (Baxter, ON, Canada) 5 ml per kg body weight per hour with 20 IU ml −1 heparin (LEO Pharma, ON, Canada)). 2.5 h into the infusion, PDX (1 µg) or vehicle was again administered to the appropriate groups, and the hyperinsulinemic-euglycemic clamp was initiated as previously described 24, 25 . The clamp protocol consisted of a 90-min tracer equilibration period followed by a 120-min experimental period. A 5-µCi bolus of [3-3 H]glucose was given at the start of the tracer equilibration period, followed by an infusion of 0.05 µCi per minute for 90 min. Blood samples were drawn for the assessment of glycemia, plasma insulin and glucose turnover. Following the 90-min tracer equilibration period, the clamp began with a primed-continuous infusion of human insulin (16 mU per kg body weight bolus followed by 4 mU per kg body weight per min, Humulin R, Eli Lilly, Indianapolis, IN). The [3-3 H]glucose infusion was increased to 0.2 µCi min −1 for the remainder of the experiment. Euglycemia (6.0-7.0 mM) was maintained during clamps by infusing 20% dextrose as necessary. Blood samples were taken continuously to determine glucosespecific activity as well as insulin concentrations. Mice received saline-washed erythrocytes from donor mice throughout the experimental period (5-6 µl min −1 ) to prevent a fall of ≥5% hematocrit. Hepatic glucose production and Rd were determined using Mari's non-steady-state equations for a twocompartmental model 26 .
For the second paired lipid infusion hyperinsulinemic-euglycemic clamp study, 10-week-old male B6.129S2-Il6 tmkopf (Il6-knockout) and genetically matched nonlittermate control (WT) mice from Jackson Labs were used. Mice from each genetic background were randomly assigned to saline-vehicle, saline-PDX, lipid-vehicle and lipid-PDX groups. The lipid-infusion clamp study was performed as described above, except the clamp was performed with an insulin infusion of 2.5 mU per kg body weight per minute 27 to ensure detection of potential differences between insulin-sensitive saline-infused animals.
The 4 mU per kg body weight hyperinsulinemic-isoglycemic clamp study was performed in 10-week-old db/db mice from the BKS.Cg-Dock7 m +/+ Lepr db strain at Jackson Labs. Mice were randomly assigned to vehicle or PDX treatment groups. In preparation for the clamps, mice were catheterized as described for the lipid infusion study. Mice were administered 2 µg of PDX or an equal volume of vehicle i.v. at 4 h and also 90 min before the initiation of the insulin pump. Preclamp glycemia was taken immediately before the second injection of PDX. The clamp began 90 min later with a primed-continuous infusion of human insulin (16 mU per kg body weight bolus followed by 4 mU per kg body weight per minute, Humulin R, Eli Lilly, Indianapolis, IN). Glycemia was maintained as close as possible to individual fasting values by infusing 20% dextrose as necessary. Blood samples were taken continuously to determine glycemia as well as insulin concentrations. Mice received saline-washed erythrocytes from donor mice throughout the experimental period (5-6 µl min −1 ) to prevent a fall of ≥5% hematocrit. The chronic PDX experiments were performed as described for the acute study, except PDX was administered twice daily at a dose of 2 µg i.v. and for five consecutive days until the day of the clamp. On clamp day, the protocol was performed precisely as described above for the acute study.
All animal procedures were approved and carried out in accordance with directions of the Laval University Council for Animal Care and the Canadian Council for Animal Care. C2C12 myotubes. C2C12 myoblasts were maintained in DMEM containing 10% FBS. Differentiation to myotubes was initiated by addition of DMEM containing 2% horse serum. The experiment was conducted 5 d after the addition of the differentiation medium. Immediately before the commencement of experiments, fresh medium was added to the cells. Next, vehicle or PDX (10 nM, 100 nM and 1 µg) was added to the appropriate wells. 30 and 120 min after the addition of PDX, medium was collected and frozen for IL-6 quantification, and cells were washed in ice-cold PBS. For extraction of mRNA, cells were then lysed and scraped in 300 µl of RLT buffer (QIAGEN). For examination of AMPK activity, cells were lysed and scraped in 200 µl of ice-cold lysis buffer containing 50 mM HEPES, pH 7.5, 150 mM NaCl, 1 mM EGTA, 20 mM β-glycerophosphate, 1% NP40, 10 mM NaF, 2 mM Na 3 VO 4 , 1× protease inhibitor cocktail (Sigma). For structure-function studies, we compared the activity of PDX (100 nM) with 100 nM of PD1, resolvin D1 (Cayman Chemical) or (8S,15S)-diHETE (Cayman Chemical). After 2 h of incubation with these lipid mediators, medium was collected and IL-6 determined as described above.
Macrophages. J774A.1 mouse macrophages (ATCC) were maintained in DMEM (10% FBS) until 80% confluence. For palmitate-stimulation studies, a 2 mM palmitate solution or methanol vehicle in Alpha MEM (12% BSA) was added to fresh DMEM (10% FBS) to give a final concentration of 400 µM palmitate. Concomitantly, PDX (10 or 100 nM, Cayman Chemical) or vehicle was added to the medium. After 16 h, the medium was collected, and cells were lysed as described for the studies in C2C12 myotubes. For IL-6-release studies, fresh DMEM (10% FBS) was added to the cells, and they were stimulated with PDX (Cayman Chemical), vehicle or LPS (100 ng mL −1 ). The medium was collected, and cells were lysed as described above.
Brown adipocytes. T37i fibroblasts were cultured in DMEM/HamF12 (Gibco-Invitrogen) supplemented with 10% FBS, 100 IU ml −1 penicillin, 100 g ml −1 streptomycin and 20 mM HEPES and grown at 37 °C in a humidified atmosphere with 5% CO 2 . Differentiation into brown adipocytes was achieved under standard conditions by incubation of subconfluent T37i cells with 2 nM triiodothyronine and 20 nM insulin for at least 7 d. Experiments were performed 7 d after differentiation. On the day of the experiment, medium was replaced and cells were stimulated with 100 nM PDX (Cayman Chemical), vehicle or norepinephrine (Sigma). The medium was collected and IL-6 determined as described above.
Western blotting. Snap-frozen gastrocnemius muscle and liver from mice were pulverized in liquid nitrogen and then lysed overnight at 4 °C in the lysis buffer described for the C2C12 myotube experiments. Immunoblotting of myotube, macrophage, liver and muscle lysates was then performed as previously described 1 . Briefly, 50 µg of protein was loaded onto a 7.5% acrylamide gel, subjected to SDS-PAGE and then transferred onto nitrocellulose membranes. Membranes were cut into regions of specific molecular weights containing the protein of interest (Akt 52-76 kDa; JNK and AMPK 38-76 kDa; STAT3 76-102 kDa; iNOS 102-150 kDa) and then blocked and probed with the appropriate antibodies. All primary antibodies were used at a concentration of 1:1,000. Secondary antibodies were diluted 1:10,000. Antibodies for pAkt Ser473 (CST9271) 1,28 , pJNK Thr183/Tyr185 (CST9251) 1,29 , JNK (CST9252) 1, 29 , pAMPK Thr172 (CST2535) 23, 30 , AMPK (CST2532) 23, 30 , pSTAT3 Ser727 (CST9134) 31, 32 and STAT3 (CST9132) 31, 32 were obtained from Cell Signaling Technology (MA, USA). Antibodies for total Akt (sc-8312) 1,28 and iNOS (610330) 1,23 were from Santa Cruz Biotechnology (CA, USA) and BD Transduction Laboratories (Canada), respectively.
Real-time RT-PCR. RNA was extracted from C2C12 myotubes using an RNeasy mini kit from QIAGEN. RNA from homogenized liver tissue was extracted using an RNeasy Fibrous Tissue Mini Kit from QIAGEN. RNA was then reverse transcribed to cDNA using the high-capacity cDNA Reverse Transcription Kit from Applied Biosystems. Real-time PCR for Ppargc1a, Pck1, G6pc and Gapdh was then performed using TaqMan assay on demand probes and primers from Applied Biosystems in a CFX96 real-time system from BIO-RAD. The relative expression of genes of interest was then determined by normalization to the reference gene Gapdh using the comparative C T method for relative gene expression 33 . npg
